ONECUT2 as a new therapeutic target in androgen receptor-indifferent prostate cancer

Michael R. Freeman, Mirja Rotinen, Sungyong You


Kaochar and Mitsiades (1) summarized in this journal the findings from two recent studies, one from our group (2), that identified the atypical homeobox protein ONECUT2 (HNF6β) as a driver of lethal prostate cancer (2,3). ONECUT2 had been identified previously as a transcriptional regulator of the prostate cancer-associated long non-coding RNA (lncRNA) PCaT1 (4), however the finding that this transcription factor (TF) plays a prominent role in a subset of aggressive prostate cancers was still unexpected.